Abstract:The orexin system comprises two G protein-coupled receptors, OX1 and OX2 receptors (OX1R and OX2R, respectively), along with two endogenous agonists cleaved from a common precursor (prepro-orexin), orexin-A (OX-A) and orexin-B (OX-B). For the receptors, a complex array of signaling behaviors has been reported. In particular, it becomes obvious that orexin receptor coupling is very diverse and can be tissue-, cell- and context-dependent. Here, the early signal transduction interactions of the orexin receptors w… Show more
“…Rodent studies indicate that the orexin system plays a role in the regulation of reward processing (7,45,46). OX neurons project to and modulate the activity of brain areas involved in reward-related behaviors including those of the mesocorticolimbic pathway and the brain's "hedonic hotspots" (8,47).…”
Section: Reward Processingmentioning
confidence: 99%
“…The orexin system comprises orexin (OX)-producing neurons that are located in a specific area of the dorso-lateral hypothalamus. OX neurons synthetize the peptide prepro-orexin, which is then cleaved to produce the two orexin peptides OX-A and OX-B (also named hypocretin-1 and hypocretin-2) (7). Axons of OX neurons project to a wide range of brain regions where OX-A and OX-B are then released (8) and bind to OX1 and OX2 receptors (OX1R, OX2R) to affect neuronal signaling (7).…”
Section: Introductionmentioning
confidence: 99%
“…OX neurons synthetize the peptide prepro-orexin, which is then cleaved to produce the two orexin peptides OX-A and OX-B (also named hypocretin-1 and hypocretin-2) (7). Axons of OX neurons project to a wide range of brain regions where OX-A and OX-B are then released (8) and bind to OX1 and OX2 receptors (OX1R, OX2R) to affect neuronal signaling (7). As such, the OX system modulates several homeostatic functions and behaviors.…”
Neuropsychiatric symptoms (NPS) affect people with dementia (PwD) almost universally across all stages of the disease, and regardless of its exact etiology. NPS lead to disability and reduced quality of life of PwD and their caregivers. NPS include hyperactivity (agitation and irritability), affective problems (anxiety and depression), psychosis (delusions and hallucinations), apathy, and sleep disturbances. Preclinical studies have shown that the orexin neuropeptide system modulates arousal and a wide range of behaviors via a network of axons projecting from the hypothalamus throughout almost the entire brain to multiple, even distant, regions. Orexin neurons integrate different types of incoming information (e.g., metabolic, circadian, sensory, emotional) and convert them into the required behavioral output coupled to the necessary arousal status. Here we present an overview of the behavioral domains influenced by the orexin system that may be relevant for the expression of some critical NPS in PwD. We also hypothesize on the potential effects of pharmacological interference with the orexin system in the context of NPS in PwD.
“…Rodent studies indicate that the orexin system plays a role in the regulation of reward processing (7,45,46). OX neurons project to and modulate the activity of brain areas involved in reward-related behaviors including those of the mesocorticolimbic pathway and the brain's "hedonic hotspots" (8,47).…”
Section: Reward Processingmentioning
confidence: 99%
“…The orexin system comprises orexin (OX)-producing neurons that are located in a specific area of the dorso-lateral hypothalamus. OX neurons synthetize the peptide prepro-orexin, which is then cleaved to produce the two orexin peptides OX-A and OX-B (also named hypocretin-1 and hypocretin-2) (7). Axons of OX neurons project to a wide range of brain regions where OX-A and OX-B are then released (8) and bind to OX1 and OX2 receptors (OX1R, OX2R) to affect neuronal signaling (7).…”
Section: Introductionmentioning
confidence: 99%
“…OX neurons synthetize the peptide prepro-orexin, which is then cleaved to produce the two orexin peptides OX-A and OX-B (also named hypocretin-1 and hypocretin-2) (7). Axons of OX neurons project to a wide range of brain regions where OX-A and OX-B are then released (8) and bind to OX1 and OX2 receptors (OX1R, OX2R) to affect neuronal signaling (7). As such, the OX system modulates several homeostatic functions and behaviors.…”
Neuropsychiatric symptoms (NPS) affect people with dementia (PwD) almost universally across all stages of the disease, and regardless of its exact etiology. NPS lead to disability and reduced quality of life of PwD and their caregivers. NPS include hyperactivity (agitation and irritability), affective problems (anxiety and depression), psychosis (delusions and hallucinations), apathy, and sleep disturbances. Preclinical studies have shown that the orexin neuropeptide system modulates arousal and a wide range of behaviors via a network of axons projecting from the hypothalamus throughout almost the entire brain to multiple, even distant, regions. Orexin neurons integrate different types of incoming information (e.g., metabolic, circadian, sensory, emotional) and convert them into the required behavioral output coupled to the necessary arousal status. Here we present an overview of the behavioral domains influenced by the orexin system that may be relevant for the expression of some critical NPS in PwD. We also hypothesize on the potential effects of pharmacological interference with the orexin system in the context of NPS in PwD.
“…3 The interaction of orexins with their receptors predominantly activates G q/11 , G s and G i/o proteins, though there is evidence of β-arrestin recruitment as well, and leads to the activation of different downstream signaling pathways, involving effectors such as cAMP, protein kinases, ion channels, and phospholipases. [4][5][6][7][8] In particular, Ca 2+ appears to be a fundamental second messenger for OX-R signaling. Orexin stimulation significantly increases the intracellular levels of Ca 2+ and this effect is predominantly mediated by phospholipase C (PLC).…”
Orexin‐A and orexin‐B, also named hypocretin‐1 and hypocretin‐2, are two hypothalamic neuropeptides highly conserved across mammalian species. Their effects are mediated by two distinct G protein‐coupled receptors, namely orexin receptor type 1 (OX1‐R) and type 2 (OX2‐R), which share 64% amino acid identity. Given the wide expression of OX‐Rs in different central nervous system and peripheral areas and the several pathophysiological functions in which they are involved, including sleep‐wake cycle regulation (mainly mediated by OX2‐R), emotion, panic‐like behaviors, anxiety/stress, food intake, and energy homeostasis (mainly mediated by OX1‐R), both subtypes represent targets of interest for many structure–activity relationship (SAR) campaigns carried out by pharmaceutical companies and academies. However, before 2017 the research was predominantly directed towards dual‐orexin ligands, and limited chemotypes were investigated. Analytical characterizations, including resolved structures for both OX1‐R and OX2‐R in complex with agonists and antagonists, have improved the understanding of the molecular basis of receptor recognition and are assets for medicinal chemists in the design of subtype‐selective ligands. This review is focused on the medicinal chemistry aspects of small molecules acting as dual or subtype selective OX1‐R/OX2‐R agonists and antagonists belonging to different chemotypes and developed in the last years, including radiolabeled OX‐R ligands for molecular imaging. Moreover, the pharmacological effects of the most studied ligands in different neuropsychiatric diseases, such as sleep, mood, substance use, and eating disorders, as well as pain, have been discussed. Poly‐pharmacology applications and multitarget ligands have also been considered.
“…Orexins also play an important role in the regulation of the neuroendocrine and autonomic nervous systems [ 5 , 6 ]. Orexins act on two G-protein-coupled receptors, orexin receptor type 1 and type 2 [ 7 ]. Orexin receptors are present in the central nervous system (CNS) and many peripheral tissues [ 8 ].…”
Cisplatin is a chemotherapeutic agent widely used in the treatment of various cancers, but its application is often limited due to complications such as acute kidney injury (AKI). Orexins are hypothalamic neuropeptides that modulate the sleep-wake cycle, neuroendocrine function, and the autonomic nervous system. Emerging evidence suggests that orexin A (OXA) has anti-inflammatory and neuroprotective effects in animal models of neuroinflammatory diseases of the central nervous system. However, the effect of OXA on kidney diseases has not been examined. Here, we investigated whether OXA has a protective effect in a murine model of cisplatin-induced AKI. Intraperitoneal administration of OXA ameliorated renal dysfunction, and histological abnormalities in mice injected with cisplatin. OXA inhibited cisplatin-induced oxidative stress through the modulation of prooxidant and antioxidant enzymes. This peptide reduced apoptotic cell death by inhibiting the p53-mediated pathway in mice injected with cisplatin. OXA also alleviated cisplatin-induced cytokine production and macrophage infiltration into injured kidneys. Taken together, these results showed that OXA ameliorates cisplatin-induced AKI via antioxidant, anti-apoptotic, and anti-inflammatory actions. This peptide could be a potential therapeutic agent for cisplatin-induced AKI.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.